Advertisement
Screener

Dyne Therapeutics, Inc. (DYN) P/E Ratio

2.8 / 5 stars · 68/120 Roast Me

Dyne Therapeutics, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

  • Dyne Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -7.09, a change of -4.45 year-over-year.
  • Dyne Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -6.63, a change of -3.39 year-over-year.
  • Dyne Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -7.23, a change of 0.37 year-over-year.
  • Dyne Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -4.26, a change of 8.15 year-over-year.
  • Dyne Therapeutics, Inc. pe ratio for fiscal 2026 was -7.09.
  • Dyne Therapeutics, Inc. pe ratio for fiscal 2025 was -7.23, a change of 0.37 from fiscal 2024.
  • Dyne Therapeutics, Inc. pe ratio for fiscal 2024 was -7.59, a change of -4.13 from fiscal 2023.
  • Dyne Therapeutics, Inc. pe ratio for fiscal 2023 was -3.47, a change of 0.37 from fiscal 2022.
Available history
2020-09-30 to 2026-06-30
Data captured

Historical PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-7.09$3.68B-$519.41M
2026-03-31-6.63$3B-$451.71M
2025-12-31-7.23$3.22B-$446.21M
2025-09-30-4.26$1.8B-$423.8M
2025-06-30-2.64$1.09B-$412.89M
2025-03-31-3.24$1.19B-$367.13M
2024-12-31-7.59$2.41B-$317.42M
2024-09-30-12.41$3.65B-$294.51M
2024-06-30-13.72$3.53B-$257.6M
2024-03-31-9.61$2.47B-$257.4M
2023-12-31-3.47$817.53M-$235.94M
2023-09-30-2.64$549.45M-$208.13M
2023-06-30-3.63$686.41M-$189.3M
2023-03-31-3.8$671.68M-$176.7M
2022-12-31-3.84$644.83M-$168.1M
2022-09-30-3.64$659.22M-$181.06M
2022-06-30-1.95$355.42M-$182.26M
2022-03-31-3.11$497.9M-$159.91M
2021-12-31-4.11$613.16M-$149.29M
2021-09-30-6.63$836.09M-$126.15M
2021-06-30-11.06$1.08B-$97.49M
2021-03-31-10.38$794.49M-$76.52M
2020-12-31-15.93$946.61M-$59.44M
2020-09-30-25.11$908.64M-$36.19M

Annual PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-7.09$3.68B-$519.41M
2025-12-31-7.23$3.22B-$446.21M
2024-12-31-7.59$2.41B-$317.42M
2023-12-31-3.47$817.53M-$235.94M
2022-12-31-3.84$644.83M-$168.1M
2021-12-31-4.11$613.16M-$149.29M
2020-12-31-15.93$946.61M-$59.44M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
Disc Medicine, Inc. (IRON)United States$2.553B-11.40